睿知中国医院研究地图
候选清单

南昌南昌大学

南昌大学第二附属医院

Second Affiliated Hospital of Nanchang University

在本站收录的 53 种疾病中,这家医院列在其中 22 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

南昌大学第二附属医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma14 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma4 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma96 篇牵头论文
  4. 胃癌Stomach cancer57 篇牵头论文
  5. 肝母细胞瘤Hepatoblastoma1 篇牵头论文
  6. 视网膜母细胞瘤Retinoblastoma2 篇牵头论文
  7. 骨肉瘤Osteosarcoma26 篇牵头论文
  8. 胃肠道间质瘤Gastrointestinal stromal tumour1 篇牵头论文
  9. 神经母细胞瘤Neuroblastoma1 篇牵头论文
  10. 多发性骨髓瘤Multiple myeloma10 篇牵头论文
  11. 非典型溶血性尿毒症综合征Atypical haemolytic uraemic syndrome1 篇牵头论文
  12. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura1 篇牵头论文
  13. 烟雾病Moyamoya disease3 篇牵头论文
  14. 肝豆状核变性Wilson disease1 篇牵头论文
  15. 大动脉炎Takayasu arteritis0 篇牵头论文
  16. 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
  17. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis2 篇牵头论文
  18. 杜氏肌营养不良Duchenne muscular dystrophy2 篇牵头论文
  19. IgA 肾病IgA nephropathy10 篇牵头论文
  20. 原发性胆汁性胆管炎Primary biliary cholangitis1 篇牵头论文
  21. 原发性硬化性胆管炎Primary sclerosing cholangitis1 篇牵头论文
  22. 家族性腺瘤性息肉病Familial adenomatous polyposis0 篇牵头论文

未列出的收录疾病:脊索瘤、尤文肉瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、胆道闭锁、抗 NMDA 受体脑炎、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、白塞病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 14 篇,占 0.6%。

牵头论文
14
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 2220232024: 3320242025: 662025

南昌有 3 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
    分期
    II期
    开始
    2024-01
    登记号
    NCT05956587

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心临沂、南昌、天津、广州、杭州、柳州、武汉、福州、西安、郑州、重庆

  2. 正在招募
    Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
    分期
    不分期
    开始
    2023-06
    登记号
    NCT05892354

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:广西医科大学第一附属医院;另有 13 家列出的医院为研究中心南宁、南昌、广州、杭州、柳州、桂林、梧州、海口、福州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题放疗技术副作用与生活质量诱导/同步化疗
论文中的科室肿瘤内科耳鼻喉/头颈外科风湿免疫科放疗科

这些论文过半是实验室或动物研究。

牵头的论文14
  1. A comparative study of different parameter estimation methods for predictive models of Normal Tissue Complication Probability (NTCP) of radiation-induced temporal lobe injury following intensity-modulated radiotherapy in nasopharyngeal carc2025BMC cancer免费全文
  2. Role of Coiled-Coil Domain-Containing Protein 86 in Tumorigenesis of Nasopharyngeal Carcinoma.2025Bulletin of experimental biology and medicine
  3. Pre-treatment serum apolipoprotein E: a promising prognostic indicator for nasopharyngeal carcinoma.2025European journal of medical research免费全文
  4. ETV5 transcriptionally activates LGR4 and promotes cancer cell invasion and migration of nasopharyngeal carcinoma.2025Journal of molecular histology
  5. ANLN knockdown inhibits nasopharyngeal carcinoma proliferation and is associated with impaired ribosome biogenesis.2025Neoplasma
  6. The NSUN2-YBX1 axis enhances 5-Methylcytosine modification to facilitate NPM1-mediated nuclear translocation of PKM2, augmenting the Warburg effect and promoting nasopharyngeal carcinoma progression in a mouse model.2025Rhinology
  7. A Neural Network-based Method for Predicting Dose to Organs at Risk in Intensity-modulated Radiotherapy for Nasopharyngeal Carcinoma.2024Clinical oncology (Royal College of Radiologists (Great Britain))
  8. Explore the shared molecular mechanism between dermatomyositis and nasopharyngeal cancer by bioinformatic analysis.2024PloS one免费全文
  9. MiR-122-5p regulates erastin-induced ferroptosis via CS in nasopharyngeal carcinoma.2024Scientific reports免费全文
  10. CCDC86 promotes the aggressive behavior of nasopharyngeal carcinoma by positively regulating EGFR and activating the PI3K/Akt signaling.2023Neoplasma
  11. Comparison of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in Lymph-Node-Stage III nasopharyngeal carcinoma based on propensity score-matching.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  12. Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial.2022BMJ open免费全文
  13. A Prospective Study on Defining the Indications of Prophylactic Level IB Radiotherapy in Nasopharyngeal Carcinoma Based on a Risk Score Model.2022Oncology research and treatment
  14. Overexpression of HOXA10 promotes the growth and metastasis of nasopharyngeal carcinoma.2021Experimental biology and medicine (Maywood, N.J.)免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
  1. Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury状态不明NCT03069820牵头方IV期2017-02 启动
  2. A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors正在招募NCT05956587研究中心II期2024-01 启动
  3. Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy正在招募NCT05892354研究中心不分期2023-06 启动
  4. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China状态不明NCT05638269研究中心2022-03 启动
  5. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma进行中,不再招募NCT04974398研究中心III期2021-08 启动
  6. Endostar for Locally Recurrent Nasopharyngeal Carcinoma状态不明NCT02636231研究中心II期2015-11 启动
PubMed 以外找到的论文(未计入)3
  1. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Research会议摘要
  2. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncology会议摘要
  3. Risk Analysis of Severe Thrombocytopenia in Nasopharyngeal Carcinoma During Concurrent Radio-Chemotherapy2021Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.1%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 0020242025: 222025

南昌有 3 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2026-08
    登记号
    NCT07700667

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 21 家列出的医院为研究中心十堰、南京、南宁、南昌、哈尔滨、天津、太原、成都、昆明、汕头、沈阳、洛阳、石家庄、福州、西安、郑州、重庆、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题分子标志物与基因影像与人工智能
论文中的科室病理/检验科
牵头的论文4
  1. AL137246.1 inhibits esophageal squamous cell carcinoma cisplatin resistance by suppressing the transcriptional activity of GLI2 on ABCC1.2025Molecular genetics and genomics : MGG
  2. ZCCHC4 regulates esophageal cancer progression and cisplatin resistance through ROS/c-myc axis.2025Scientific reports免费全文
  3. Prognostic value and immune landscapes of cuproptosis-related lncRNAs in esophageal squamous cell carcinoma.2023Aging免费全文
  4. USP18 promotes tumor metastasis in esophageal squamous cell carcinomas via deubiquitinating ZEB1.2021Experimental cell research
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma正在招募NCT07700667研究中心II期2026-08 启动
  2. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.已完成NCT05142709研究中心2021-10 启动
  3. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT04732494研究中心II期2021-03 启动
  4. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03783442研究中心III期2018-12 启动
PubMed 以外找到的论文(未计入)3
  1. WITHDRAWN: 2143P Impact of first-line chemoimmunotherapy with or without radiotherapy on the prognosis of patients with locally advanced or metastatic esophageal squamous cell carcinoma: A multicenter, real-world, retrospective cohort study2025Annals of Oncology撤稿
  2. Leveraging cfDNA fragmentomic features in a stacked ensemble model for early detection of esophageal squamous cell carcinoma.2024Journal of Clinical Oncology会议摘要
  3. Additional file 2 of FBXW7 loss of function promotes esophageal squamous cell carcinoma progression via elevating MAP4 and ERK phosphorylation2023Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 96 篇,占 0.7%。

牵头论文
96
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
6
由其他机构牵头
每年牵头的论文数
2021: 121220212022: 161620222023: 222220232024: 202020242025: 22222025

南昌有 3 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

这家医院参与的开放试验 6

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    分期
    I期
    开始
    2025-11
    登记号
    NCT07176650

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、海口、石家庄、福州、蚌埠、西安、郑州、长春

  2. 正在招募
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    分期
    II期
    开始
    2025-06
    登记号
    NCT07327034

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙

  3. 正在招募
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06427941

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、福州、重庆、长沙

  4. 正在招募
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    分期
    III期
    开始
    2023-05
    登记号
    NCT05862337

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、大连、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙

  5. 正在招募
    Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
    分期
    未注明
    开始
    2022-09
    登记号
    NCT06822413

    年龄未注明(登记的条件)

    牵头:浙江大学医学院附属第二医院;另有 3 家列出的医院为研究中心上海、南昌、杭州

  6. 即将招募
    Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC
    分期
    不分期
    开始
    2026-10
    登记号
    NCT07596134

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心南昌、台州、杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后免疫与靶向药物影像、人工智能与早期发现
论文中的科室普外/肝胆胰外科肿瘤内科消化/肝病科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文96
  1. TMEM44 as a Novel Prognostic Marker for Hepatocellular Carcinoma is Associated with Tumor Invasion, Migration, and Apoptosis.2026Biochemical genetics
  2. NCAPG confers ferroptosis resistance of hepatocellular carcinoma through NSUN2-mediated m5C modification.2026Cellular signalling
  3. Diosgenin targets ITGA11-driven angiogenesis in hepatocellular carcinoma: Prognostic and mechanistic insights.2026Computational biology and chemistry
  4. BAG6 promotes hepatocellular carcinoma growth via enhancing PLK1-mediated aerobic glycolysis.2026International journal of biological macromolecules
  5. Comparative efficacy of tislelizumab plus lenvatinib and tislelizumab alone against advanced hepatocellular carcinoma after lenvatinib failure: a real-world study.2025BMC cancer免费全文
  6. ACSM5 Regulates Ferroptosis in Hepatocellular Carcinoma by Up-Regulating POR and Modulating Lipid Metabolism.2025Cancer science免费全文
  7. SIRPα blockade therapy potentiates immunotherapy by inhibiting PD-L1+ myeloid cells in hepatocellular carcinoma.2025Cell death & disease免费全文
  8. NUB1 reduction promotes PCNA-mediated tumor growth by disturbing the PCNA polyubiquitination/NEDDylation in hepatocellular carcinoma cells.2025Cell death & disease免费全文
  9. Elevated P4HB expression in hepatocellular carcinoma and its role in UCA1-mediated malignant progression.2025Cellular signalling
  10. NCAPG promotes epithelial-mesenchymal transition through SIP-dependent ubiquitination regulation of β-catenin in hepatocellular carcinoma.2025Cellular signalling
  11. AHCTF1 Functions as an Oncogenic Factor and Promotes Tumor Progression in Hepatocellular Carcinoma.2025Digestive diseases and sciences免费全文
  12. XPD Regulates MIAT/miR-29a-3p/COL4A1 Axis to Impede Hepatocellular Carcinoma Development.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  13. Plasma exosomal lncRNA-related signatures define molecular subtypes and predict survival and treatment response in hepatocellular carcinoma.2025Frontiers in immunology免费全文
  14. PSMD12 promotes hepatocellular carcinoma progression by stabilizing CDK1.2025Frontiers in immunology免费全文
  15. DDX1 facilitates lenvatinib resistance in hepatocellular carcinoma through regulating ephrin-A3 and activating the Wnt/β-catenin signaling pathway.2025Functional & integrative genomics
  16. Rapid detection of plasma exosomal LncRNA CASC9 for HCC using RT-RPA-CRISPR/Cas12a assay.2025Journal of pharmaceutical and biomedical analysis
  17. High interstitial fluid pressure enhances USP1-dependent KIF11 protein stability to promote hepatocellular carcinoma progression.2025Journal of translational medicine免费全文
  18. METTL3-mediated TUG1 regulation of miR-9 in doxorubicin resistance in HCC.2025Life sciences
  19. Comprehensive Bioinformatics Analysis and Machine Learning of TTK as a Transhepatic Arterial Chemoembolization Resistance Target in Hepatocellular Carcinoma.2025Molecular biotechnology
  20. Mechanism of atorvastatin in treating hepatocellular carcinoma: a study based on network pharmacology, molecular docking, and bioinformatics analysis.2025Naunyn-Schmiedeberg's archives of pharmacology
  21. Modeling the prediction of spontaneous rupture and bleeding in hepatocellular carcinoma via machine learning algorithms.2025Scientific reports免费全文
  22. The m6A reader IGF2BP3 promotes HCC progression by enhancing MCM10 stability.2025Scientific reports免费全文
  23. hsa_circ_0008305 facilitates the malignant progression of hepatocellular carcinoma by regulating AKR1C3 expression and sponging miR-379-5p.2025Scientific reports免费全文
  24. Multiomic characterization, immunological and prognostic potential of SMAD3 in pan-cancer and validation in LIHC.2025Scientific reports免费全文
  25. Comparative efficacy and safety of lenvatinib, sintilimab combined interventional therapy vs bevacizumab, sintilimab combined interventional therapy in intermediate and advanced hepatocellular carcinoma: a multicenter retrospective study.2025World journal of surgical oncology免费全文
  26. A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma with esophagogastric varices after progression on first-line lenvatinib combined with PD-1 inhibitor.2025World journal of surgical oncology免费全文
  27. Comprehensive prognostic and immunological analysis of Cullin2 in pan-cancer and its identification in hepatocellular carcinoma.2024Aging免费全文
  28. Development of machine learning-based personalized predictive models for risk evaluation of hepatocellular carcinoma in hepatitis B virus-related cirrhosis patients with low levels of serum alpha-fetoprotein.2024Annals of hepatology
  29. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.2024Cancer medicine免费全文
  30. Ropivacaine synergizes with sorafenib to induce apoptosis of hepatocellular carcinoma cells via the IL-6/STAT3 pathway.2024Cancer science免费全文
  31. USP11 promotes lipogenesis and tumorigenesis by regulating SREBF1 stability in hepatocellular carcinoma.2024Cell communication and signaling : CCS免费全文
  32. SNRPB2 in the pan-cancer landscape: A bioinformatics exploration and validation in hepatocellular carcinoma.2024Cellular signalling
  33. PSMD11 promotes the proliferation of hepatocellular carcinoma by regulating the ubiquitination degradation of CDK4.2024Cellular signalling
  34. Ropivacaine combined with sorafenib attenuates hepatocellular carcinoma cell proliferation and metastasis by inhibiting the miR-224/HOXD10 axis.2024Environmental toxicology
  35. Knockdown of circZMIZ1 enhances the anti-tumor activity of CD8+ T cells to alleviate hepatocellular carcinoma.2024Functional & integrative genomics
  36. SRSF7 is a promising prognostic biomarker in hepatocellular carcinoma and is associated with immune infiltration.2024Genes & genomics
  37. The ubiquitin-like protein FAT10 in hepatocellular carcinoma cells limits the efficacy of anti-VEGF therapy.2024Journal of advanced research免费全文
  38. Homeobox B9 promotes the invasion and metastasis of hepatocellular carcinoma cells via the EZH2-MIR203A-SNAI2 axis.2024Journal of translational medicine免费全文
  39. AC099850.3 promotes HBV-HCC cell proliferation and invasion through regulating CD276: a novel strategy for sorafenib and immune checkpoint combination therapy.2024Journal of translational medicine免费全文
  40. The HHEX-ABI2/SLC17A9 axis induces cancer stem cell-like properties and tumorigenesis in HCC.2024Journal of translational medicine免费全文
  41. BarH-Like Homeobox 2 Suppresses Cell Proliferation, Invasion, and Angiogenesis in Hepatocellular Carcinoma by Activating N-Acetylgalactosaminyltransferase 4.2024Molecular biotechnology
  42. Hepatic Symbiotic Bacterium L. reuteri FLRE5K1 Inhibits the Development and Progression of Hepatocellular Carcinoma via Activating the IFN-γ/CXCL10/CXCR3 Pathway.2024Probiotics and antimicrobial proteins
  43. Comparative analysis of the safety and feasibility of laparoscopic and open approaches for right anterior sectionectomy.2024Scientific reports免费全文
  44. SNX16 is required for hepatocellular carcinoma survival via modulating the EGFR-AKT signaling pathway.2024Scientific reports免费全文
  45. PD-1/PD-L1 Inhibitors Plus Antiangiogenic Drugs Versus Sorafenib as the First Line Treatment for Advanced Hepatocellular Carcinoma: A Phase 3 RCTs Based Meta-Analysis.2024Technology in cancer research & treatment免费全文
  46. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.2024World journal of surgical oncology免费全文
  47. ZNF765 is a prognostic biomarker of hepatocellular carcinoma associated with cell cycle, immune infiltration, m6A modification, and drug susceptibility.2023Aging免费全文
  48. FARSB serves as a novel hypomethylated and immune cell infiltration related prognostic biomarker in hepatocellular carcinoma.2023Aging免费全文
  49. Comprehensive analysis reveals TSEN54 as a robust prognosis biomarker and promising immune-related therapeutic target for hepatocellular carcinoma.2023Aging免费全文
  50. Biological function analysis of ARHGAP39 as an independent prognostic biomarker in hepatocellular carcinoma.2023Aging免费全文
  51. Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China.2023BMC cancer免费全文
  52. Network meta-analysis of adjuvant treatments for patients with hepatocellular carcinoma after curative resection.2023BMC gastroenterology免费全文
  53. Signature construction and molecular subtype identification based on immune-related genes for better prediction of prognosis in hepatocellular carcinoma.2023BMC medical genomics免费全文
  54. Prognostic value and immune landscapes of immunogenic cell death-related lncRNAs in hepatocellular carcinoma.2023Bioscience reports免费全文
  55. Efficacy and Safety of Drug-Eluting Bead TACE in the Treatment of Primary or Secondary Liver Cancer.2023Canadian journal of gastroenterology & hepatology免费全文
  56. The deubiquitinating enzyme USP44 suppresses hepatocellular carcinoma progression by inhibiting Hedgehog signaling and PDL1 expression.2023Cell death & disease免费全文
  57. CKLF as a Prognostic Biomarker and Its Association with Immune Infiltration in Hepatocellular Carcinoma.2023Current oncology (Toronto, Ont.)免费全文
  58. Combining bulk and single-cell RNA-sequencing data to develop an NK cell-related prognostic signature for hepatocellular carcinoma based on an integrated machine learning framework.2023European journal of medical research免费全文
  59. Validation of a supplementary condition of eighth AJCC staging system for stage II hepatocellular carcinoma.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  60. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.2023Frontiers in immunology免费全文
  61. Molecular subtype identification and signature construction based on Golgi apparatus-related genes for better prediction prognosis and immunotherapy response in hepatocellular carcinoma.2023Frontiers in immunology免费全文
  62. Comprehensive bioinformatics analysis of a RBM family-based prognostic signature with experiment validation in hepatocellular carcinoma.2023Journal of cancer research and clinical oncology免费全文
  63. Biejia-Ruangan compound and incidence of hepatocellular carcinoma.2023Journal of hepatology
  64. NOP2-mediated m5C methylation of XPD is associated with hepatocellular carcinoma progression.2023Neoplasma
  65. Identification of M2-like macrophage-related signature for predicting the prognosis, ecosystem and immunotherapy response in hepatocellular carcinoma.2023PloS one免费全文
  66. LncTUG1 promotes hepatocellular carcinoma immune evasion via upregulating PD-L1 expression.2023Scientific reports免费全文
  67. Pancancer analysis of oncogenic BARX2 identifying its prognostic value and immunological function in liver hepatocellular carcinoma.2023Scientific reports免费全文
  68. Based on the IWATE criteria: to investigate the influence of different surgical approaches on the perioperative outcomes of hepatectomy.2023Surgical endoscopy
  69. Comprehensive analysis of prognostic value, relationship to cell cycle, immune infiltration and m6A modification of ZSCAN20 in hepatocellular carcinoma.2022Aging免费全文
  70. Desmocollin-2 inhibits cell proliferation and promotes apoptosis in hepatocellular carcinoma via the ERK/c-MYC signaling pathway.2022Aging免费全文
  71. ZNF320 is a hypomethylated prognostic biomarker involved in immune infiltration of hepatocellular carcinoma and associated with cell cycle.2022Aging免费全文
  72. Enhancer of zeste homolog 2 promotes hepatocellular cancer progression and chemoresistance by enhancing protein kinase B activation through microRNA-381-mediated SET domain bifurcated 1.2022Bioengineered免费全文
  73. TP53 mutation detected in circulating exosomal DNA is associated with prognosis of patients with hepatocellular carcinoma.2022Cancer biology & therapy免费全文
  74. O-GlycNacylation Remission Retards the Progression of Non-Alcoholic Fatty Liver Disease.2022Cells免费全文
  75. MiR-27a-3p targets USP46 to inhibit the cell proliferation of hepatocellular carcinoma.2022Chemical biology & drug design
  76. A Pyroptosis-Related Gene Signature to Predict Patients' Prognosis and Immune Landscape in Liver Hepatocellular Carcinoma.2022Computational and mathematical methods in medicine免费全文
  77. Identification of a Necroptosis-Related Prognostic Signature and Associated Regulatory Axis in Liver Hepatocellular Carcinoma.2022Disease markers免费全文
  78. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.2022Frontiers in immunology免费全文
  79. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.2022Frontiers in immunology免费全文
  80. Construction of a Novel LncRNA Signature Related to Genomic Instability to Predict the Prognosis and Immune Activity of Patients With Hepatocellular Carcinoma.2022Frontiers in immunology免费全文
  81. NCAPG promotes the proliferation of hepatocellular carcinoma through the CKII-dependent regulation of PTEN.2022Journal of translational medicine免费全文
  82. miR-2392 serves as an immunological and prognostic biomarker in hepatocellular carcinoma.2022Liver international : official journal of the International Association for the Study of the Liver
  83. Circ-ZEB1 promotes PIK3CA expression by silencing miR-199a-3p and affects the proliferation and apoptosis of hepatocellular carcinoma.2022Molecular cancer免费全文
  84. DLGAP4 acts as an effective prognostic predictor for hepatocellular carcinoma and is closely related to tumour progression.2022Scientific reports免费全文
  85. The deubiquitinase OTUD3 stabilizes ACTN4 to drive growth and metastasis of hepatocellular carcinoma.2021Aging免费全文
  86. Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database.2021BMC cancer免费全文
  87. Modified median hepatic fissure approach for resection of liver tumours located in the angle between the root of the middle and right hepatic veins.2021BMC surgery免费全文
  88. Comprehensive analysis of N6-methyladenosine -related long non-coding RNAs and immune cell infiltration in hepatocellular carcinoma.2021Bioengineered免费全文
  89. COL4A1, negatively regulated by XPD and miR-29a-3p, promotes cell proliferation, migration, invasion and epithelial-mesenchymal transition in liver cancer cells.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  90. Comparing the diagnostic value of serum oligosaccharide chain (G-test) and alpha-fetoprotein for hepatitis B virus-related liver cancer.2021Clinical biochemistry
  91. Deubiquitinating enzyme USP46 suppresses the progression of hepatocellular carcinoma by stabilizing MST1.2021Experimental cell research
  92. Long noncoding RNA LEF1-AS1 acts as a microRNA-10a-5p regulator to enhance MSI1 expression and promote chemoresistance in hepatocellular carcinoma cells through activating AKT signaling pathway.2021Journal of cellular biochemistry
  93. A novel prognostic index of hepatocellular carcinoma based on immunogenomic landscape analysis.2021Journal of cellular physiology
  94. Silencing of ATG4D suppressed proliferation and enhanced cisplatin-induced apoptosis in hepatocellular carcinoma through Akt/Caspase-3 pathway.2021Molecular and cellular biochemistry
  95. Vaccinia-related kinase 2 blunts sorafenib's efficacy against hepatocellular carcinoma by disturbing the apoptosis-autophagy balance.2021Oncogene
  96. A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection.2021World journal of surgical oncology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)14
  1. HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC状态不明NCT05582278牵头方(推断)II期2021-01 启动
  2. Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC即将招募NCT07596134研究中心不分期2026-10 启动
  3. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression正在招募NCT07327034研究中心II期2025-06 启动
  4. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma正在招募NCT07176650研究中心I期2025-11 启动
  5. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  6. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.正在招募NCT05862337研究中心III期2023-05 启动
  7. Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis正在招募NCT06822413研究中心2022-09 启动
  8. A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)已终止NCT06487559研究中心I期2024-09 启动
  9. Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)状态不明NCT05594927研究中心III期2022-12 启动
  10. A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC已完成NCT04948697研究中心II期2021-08 启动
  11. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC已完成NCT04723004研究中心III期2020-10 启动
  12. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma进行中,不再招募NCT04194775研究中心III期2019-12 启动
  13. Study of BGB-A317 in Participants With Previously Treated Unresectable HCC已完成NCT03419897研究中心II期2018-04 启动
  14. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)已完成NCT03412773研究中心III期2017-12 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 57 篇,占 0.6%。

牵头论文
57
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 111120212022: 4420222023: 8820232024: 191920242025: 12122025

南昌有 3 家医院列在胃癌下全国有 211 家医院列在胃癌下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    分期
    III期
    开始
    2026-12
    登记号
    NCT07789184

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 25 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南昌、大连、天津、广州、杭州、武汉、济南、西安、重庆、长春、青岛

  2. 正在招募
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06427941

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、重庆、长沙

  3. 正在招募
    Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
    分期
    未注明
    开始
    2022-09
    登记号
    NCT06822413

    年龄未注明(登记的条件)

    牵头:浙江大学医学院附属第二医院;另有 3 家列出的医院为研究中心上海、南昌、杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题影像与人工智能腹膜转移与晚期免疫与靶向药物
论文中的科室普外/肝胆胰外科消化/肝病科影像/核医学科肿瘤内科
牵头的论文57
  1. A Network Information-Based Behavior Change Wheel for Populations at High Risk of Developing Gastric Cancer.2026Journal of cancer education : the official journal of the American Association for Cancer Education
  2. The Role of Yes-Associated Protein in Autophagy and Tumor Progression in Gastric Cancer.2026Molecular biotechnology
  3. P2Y2 receptor as a favorable predictor of gastric cancer.2026Tissue & cell
  4. MR Promotes Ferroptosis in Gastric Cancer by Regulating FANCD2 Expression Mediated by m6A Modification.2025Applied biochemistry and biotechnology
  5. Comprehensive analysis of ferroptosis-related long non-coding RNA and its association with tumor progression and ferroptosis in gastric cancer.2025BMC gastroenterology免费全文
  6. Methionine Restriction Exerts Anti-Tumor Immunity via Joint Intervention of T-Bet Palmitoylation in Gastric Cancer.2025Biotechnology journal
  7. Lectin-affinity glycosylation pattern analysis of plasma extracellular vesicles: An all-in-one clinical assessment for gastric cancer diagnosis and treatment.2025Cancer letters
  8. HNF4A promotes tumor progression in gastric cancer by transcriptional activation of KIF2C.2025Clinical and experimental medicine免费全文
  9. Skeletal muscle gauge: A superior predictor of neoadjuvant chemoimmunotherapy efficacy in locally advanced gastric cancer.2025Clinical nutrition ESPEN
  10. TFAP4 Regulation of MCM5 Activates the PI3K/AKT Pathway to Promote Invasion and Metastasis of Gastric Cancer.2025Digestive diseases and sciences
  11. ChatGPT-4o outperforms gemini advanced in assisting multidisciplinary decision-making for advanced gastric cancer.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  12. A Golgi apparatus-related signature predicts the immune microenvironment and prognosis of gastric cancer.2025Genes and immunity
  13. P2X7 receptor promotes the growth and metastasis of gastric cancer by activating P13/AKT/GSK-3 beta signaling (experimental research).2025International journal of surgery (London, England)免费全文
  14. The functional role of P2 purinergic receptors in the progression of gastric cancer.2025Purinergic signalling免费全文
  15. Research Progress in Clinical Applications of Gastric Contrast-Enhanced Ultrasound.2025Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  16. Upregulation of E-cadherin by the combination of methionine restriction and HDAC2 intervention for inhibiting gastric carcinoma metastasis.2024Acta biochimica et biophysica Sinica免费全文
  17. Influence of Postoperative Insulin Resistance on Short-Term Outcomes of Radical Gastrectomy for Gastric Cancer: A Microbiome and Metabolome-Based Prospective Cohort Study.2024Annals of surgical oncology
  18. Probiotic Compounds Enhanced Recovery after Surgery for Patients with Distal Gastric Cancer: A Prospective, Controlled Clinical Trial.2024Annals of surgical oncology
  19. PANoptosis subtypes predict prognosis and immune efficacy in gastric cancer.2024Apoptosis : an international journal on programmed cell death
  20. Methionine restriction attenuates the migration and invasion of gastric cancer cells by inhibiting nuclear p65 translocation through TRIM47.2024Biological chemistry
  21. Disulfidptosis signature predicts immune microenvironment and prognosis of gastric cancer.2024Biology direct免费全文
  22. The Role of Methionine Restriction in Gastric Cancer: A Summary of Mechanisms and a Discussion on Tumor Heterogeneity.2024Biomolecules免费全文
  23. Construction of a disulfidptosis-related glycolysis gene risk model to predict the prognosis and immune infiltration analysis of gastric adenocarcinoma.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  24. Methionine restriction promotes cisplatin sensitivity of gastric cancer resistant cells by down-regulating circ-CDK13 level.2024Experimental cell research
  25. KLF10/CBS increases the sensitivity of gastric carcinoma cells to methionine restriction by promoting sulfur transfer pathway.2024Experimental cell research
  26. Inflammatory burden index as a prognostic marker in patients with advanced gastric cancer treated with neoadjuvant chemotherapy and immunotherapy.2024Frontiers in immunology免费全文
  27. Machine learning to predict distant metastasis and prognostic analysis of moderately differentiated gastric adenocarcinoma patients: a novel focus on lymph node indicators.2024Frontiers in immunology免费全文
  28. Exosome as a crucial communicator between tumor microenvironment and gastric cancer (Review).2024International journal of oncology免费全文
  29. Identification roles of NFE2L3 in digestive system cancers.2024Journal of cancer research and clinical oncology免费全文
  30. The relationship between periodontal disease and gastric cancer: A bidirectional Mendelian randomization study.2024Medicine免费全文
  31. A degradome-related signature for predicting the prognosis and immunotherapy benefit in stomach adenocarcinoma based on machine learning procedure.2024Medicine免费全文
  32. Machine learning-based cell death signature for predicting the prognosis and immunotherapy benefit in stomach adenocarcinoma.2024Medicine免费全文
  33. Development and external validation of a nomogram predicting overall survival for Gastric adenocarcinoma patients with radical gastrectomy.2024Scandinavian journal of gastroenterology
  34. Role of P2X7 receptor in the progression and clinicopathological characteristics of gastric cancer.2024Scientific reports免费全文
  35. An immunogenic cell death-related signature predicts prognosis and immunotherapy response in stomach adenocarcinoma.2023Apoptosis : an international journal on programmed cell death
  36. AKT/GSK-3beta/VEGF signaling is involved in P2RY2 activation-induced the proliferation and metastasis of gastric cancer.2023Carcinogenesis
  37. Landscapes and mechanisms of CD8+ T cell exhaustion in gastrointestinal cancer.2023Frontiers in immunology免费全文
  38. Target tumor therapy in human gastric cancer cells through the combination of docetaxel-loaded cationic lipid microbubbles and ultrasound-triggered microbubble destruction.2023Functional & integrative genomics
  39. SKAP1 Is a Novel Biomarker and Therapeutic Target for Gastric Cancer: Evidence from Expression, Functional, and Bioinformatic Analyses.2023International journal of molecular sciences免费全文
  40. LncRNA POU6F2-AS2 contributes to malignant phenotypes and paclitaxel resistance by promoting SKP2 expression in stomach adenocarcinoma.2023Journal of chemotherapy (Florence, Italy)
  41. Cancer functional states-based molecular subtypes of gastric cancer.2023Journal of translational medicine免费全文
  42. Identification of a basement membrane-related genes signature to predict prognosis, immune landscape and guide therapy in gastric cancer.2023Medicine免费全文
  43. Toll-like receptor 3 is a potential prognosis marker and associated with immune infiltration in stomach adenocarcinoma.2022Cancer biomarkers : section A of Disease markers免费全文
  44. Clostridium butyricum potentially improves inflammation and immunity through alteration of the microbiota and metabolism of gastric cancer patients after gastrectomy.2022Frontiers in immunology免费全文
  45. The Hypoxic Landscape Stratifies Gastric Cancer Into 3 Subtypes With Distinct M6a Methylation and Tumor Microenvironment Infiltration Characteristics.2022Frontiers in immunology免费全文
  46. Meta-analysis of the prognostic value of circulating tumor cells in gastrointestinal cancer.2022Medicine免费全文
  47. The circadian clock is associated with prognosis and immune infiltration in stomach adenocarcinoma.2021Aging免费全文
  48. Constructing a new prognostic signature of gastric cancer based on multiple data sets.2021Bioengineered免费全文
  49. Establishment of a prognostic model of four genes in gastric cancer based on multiple data sets.2021Cancer medicine免费全文
  50. USP1 Promotes GC Metastasis via Stabilizing ID2.2021Disease markers免费全文
  51. Transfer of LncRNA CRNDE in TAM-derived exosomes is linked with cisplatin resistance in gastric cancer.2021EMBO reports免费全文
  52. Adjuvant treatment and molecular mechanism of probiotic compounds in patients with gastric cancer after gastrectomy.2021Food & functionRCT
  53. Establishment of a prognostic model of ten transcription factors in gastric cancer.2021Genomics
  54. Combining the platelet-to-albumin ratio with serum and pathologic variables to establish a risk assessment model for lymph node metastasis of gastric cancer.2021Journal of biological regulators and homeostatic agents
  55. Long noncoding RNA TUG1 upregulates VEGFA to enhance malignant behaviors in stomach adenocarcinoma by sponging miR-29c-3p.2021Journal of clinical laboratory analysis免费全文
  56. Exosome-mediated transfer of lncRNA HCG18 promotes M2 macrophage polarization in gastric cancer.2021Molecular immunology
  57. Methionine deficiency promoted mitophagy via lncRNA PVT1-mediated promoter demethylation of BNIP3 in gastric cancer.2021The international journal of biochemistry & cell biology
中文论文(未计入)1
  1. [Expression characteristics and functional analysis of ELK3 in gastric cancer].2021Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)9
  1. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy正在招募NCT07789184研究中心III期2026-12 启动
  2. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  3. Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis正在招募NCT06822413研究中心2022-09 启动
  4. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)进行中,不再招募NCT06356311研究中心III期2024-05 启动
  5. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China状态不明NCT05638269研究中心2022-03 启动
  6. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer进行中,不再招募NCT05180734研究中心III期2022-02 启动
  7. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection进行中,不再招募NCT04581473研究中心I/II期2020-10 启动
  8. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)状态不明NCT02461407研究中心II/III期2015-06 启动
  9. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

南昌有 2 家医院列在肝母细胞瘤下全国有 86 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

南昌有 8 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 26 篇,占 1.1%。

牵头论文
26
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 3320222023: 4420232024: 111120242025: 552025

南昌有 7 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文26
  1. Reversal of MPPa-PDT Resistance in Osteosarcoma by Targeting ROCK2-Mediated Autophagy.2026Cell proliferation
  2. Silencing Livin gene expression by RNA interference enhanced the chemotherapeutic sensitivity of drug-resistant osteosarcoma cells to doxorubicin.2025Acta histochemica
  3. Identification and functional characterization of T-cell exhaustion-associated lncRNA AL031775.1 in osteosarcoma: a novel therapeutic target.2025Frontiers in immunology
  4. ACSL4 accelerates osteosarcoma progression via modulating TGF-β/Smad2 signaling pathway.2025Molecular and cellular biochemistry
  5. Downregulation of ferroptosis-related Genes can regulate the invasion and migration of osteosarcoma cells.2025Scientific reports
  6. Long non-coding RNA AC133552.2: biomarker and therapeutic target in osteosarcoma via PANoptosis gene screening.2025Scientific reports
  7. Bioinformatics analysis and validation of mesenchymal stem cells related gene MT1G in osteosarcoma.2024Aging
  8. Molecular characterization of Golgi apparatus-related genes indicates prognosis and immune infiltration in osteosarcoma.2024Aging
  9. LncRNA RPARP-AS1 promotes the progression of osteosarcoma cells through regulating lipid metabolism.2024BMC cancer
  10. The role of programmed cell death in osteosarcoma: From pathogenesis to therapy.2024Cancer medicine
  11. New insights into the role of mitophagy related gene affecting the metastasis of osteosarcoma through scRNA-seq and CRISPR-Cas9 genome editing.2024Cell communication and signaling : CCS
  12. Curcumin suppresses metastasis, invasion, and proliferation in osteosarcoma cells by regulating the EGFR/Src signaling axis.2024International journal of immunopathology and pharmacology
  13. USP22 Promotes Osteosarcoma Progression by Stabilising β-Catenin and Upregulating HK2 and Glycolysis.2024Journal of cellular and molecular medicine
  14. The prognostic value of ubiquitin/ubiquitin-like-related genes along with immune cell infiltration and clinicopathological features in osteosarcoma.2024Journal of orthopaedic surgery and research
  15. Hydroxysafflor yellow A induced ferroptosis of Osteosarcoma cancer cells by HIF-1α/HK2 and SLC7A11 pathway.2024Oncology research
  16. USP22 as a key regulator of glycolysis pathway in osteosarcoma: insights from bioinformatics and experimental approaches.2024PeerJ
  17. Development and validation of a novel endoplasmic reticulum stress-related lncRNAs signature in osteosarcoma.2024Scientific reports
  18. Identification of mitochondrial-related signature and molecular subtype for the prognosis of osteosarcoma.2023Aging
  19. Molecular characterization of cancer-intrinsic immune evasion genes indicates prognosis and tumour microenvironment infiltration in osteosarcoma.2023Aging
  20. Deubiquitinating enzyme USP10 promotes osteosarcoma metastasis and epithelial-mesenchymal transition by stabilizing YAP1.2023Cancer medicine
  21. Exploring the immune microenvironment of osteosarcoma through T cell exhaustion-associated gene expression: a study on prognosis prediction.2023Frontiers in immunology
  22. Mechanism and Role of Endoplasmic Reticulum Stress in Osteosarcoma.2022Biomolecules
  23. Hsp90 regulates the tumorigenic function of tyrosine protein kinase in osteosarcoma.2022Clinical and experimental pharmacology & physiology
  24. The Cuproptosis-Related Long Noncoding RNA Signature Predicts Prognosis and Tumour Immune Analysis in Osteosarcoma.2022Computational and mathematical methods in medicine
  25. Low GNG12 Expression Predicts Adverse Outcomes: A Potential Therapeutic Target for Osteosarcoma.2021Frontiers in immunology
  26. Revealing the link between macrophage in microenvironment of osteosarcoma and poor prognosis by utilizing the Integrated analysis.2021Journal of musculoskeletal & neuronal interactions
早期论文(2016–2020 年)6
  1. Ubiquitin-like protein FAT10 promotes osteosarcoma growth by modifying the ubiquitination and degradation of YAP1.2020Experimental cell research
  2. ROCK2 promotes osteosarcoma growth and metastasis by modifying PFKFB3 ubiquitination and degradation.2019Experimental cell research
  3. Meta-analysis of alkaline phosphatase and prognosis for osteosarcoma.2017European journal of cancer care
  4. [Effect of ursolic acid on proliferation and apoptosis of human osteosarcoma cell line U2-OS].2017Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  5. Id-1 promotes osteosarcoma cell growth and inhibits cell apoptosis via PI3K/AKT signaling pathway.2016Biochemical and biophysical research communications
  6. High level of αB-crystallin contributes to the progression of osteosarcoma.2016Oncotarget

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

南昌有 4 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科
牵头的论文1
  1. Expression of DOG1 in peripheral blood cells of patients with gastrointestinal stromal tumor.2021Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Second-line Pharmacotherapy Patterns and Outcomes of Advanced Gastrointestinal Stromal Tumor: A Real-world Study状态不明NCT05440357研究中心2022-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

南昌有 4 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 10 篇,占 0.6%。

牵头论文
10
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 1120232024: 5520242025: 222025

南昌有 2 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    分期
    I期
    开始
    2026-05
    登记号
    NCT07477587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛

  2. 即将招募
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-06
    登记号
    NCT07569757

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、徐州、成都、承德、昆明、杭州、株洲、沈阳、泸州、济南、湛江、石家庄、蚌埠、西安、贵阳、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层CAR-T 与细胞治疗干细胞移植
论文中的科室病理/检验科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文10
  1. Serum ferritin as a prognostic biomarker in CAR-T therapy for multiple myeloma: A meta-analysis.2025Biomolecules & biomedicine免费全文
  2. METTL5 regulates SEPHS2-mediated selenoprotein synthesis to promote multiple myeloma survival and progression.2025Cell death & disease免费全文
  3. An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously.2024Cancer gene therapy免费全文
  4. lncRNA H19 plays a role in multiple myeloma via interacting with hnRNPA2B1 to stabilize BET proteins by targeting osteoclasts and osteoblasts.2024International immunopharmacology
  5. Exosomal lncRNA NEAT1 Inhibits NK-Cell Activity to Promote Multiple Myeloma Cell Immune Escape via an EZH2/PBX1 Axis.2024Molecular cancer research : MCR
  6. The value of myocardial contraction fraction and long-axis strain to predict late gadolinium enhancement in multiple myeloma patients with secondary cardiac amyloidosis.2024Scientific reports免费全文
  7. A Novel Necroptosis-Related Signature Can Predict Prognosis and Chemotherapy Sensitivity in Multiple Myeloma.2024Technology in cancer research & treatment免费全文
  8. Abnormal expression pattern of lncRNA H19 participates in multiple myeloma bone disease by unbalancing osteogenesis and osteolysis.2023International immunopharmacology
  9. Diallyl thiosulfinate enhanced the anti-cancer activity of dexamethasone in the side population cells of multiple myeloma by promoting miR-127-3p and deactivating the PI3K/AKT signaling pathway.2021BMC cancer免费全文
  10. Multiple myeloma with CD138 changed from positive to negative: A case report.2021Cytometry. Part B, Clinical cytometry
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma即将招募NCT07569757研究中心III期2026-06 启动
  2. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma正在招募NCT07477587研究中心I期2026-05 启动
  3. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03952091研究中心III期2019-03 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

非典型溶血性尿毒症综合征

Atypical haemolytic uraemic syndrome

2021–2025 年中国大陆作者发表的 27 篇非典型溶血性尿毒症综合征 PubMed 英文论文中,这家医院牵头了 1 篇,占 3.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

南昌有 2 家医院列在非典型溶血性尿毒症综合征下全国有 31 家医院列在非典型溶血性尿毒症综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的非典型溶血性尿毒症综合征开放试验。

这些数字背后的记录
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

南昌有 2 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

烟雾病

Moyamoya disease

2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.8%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 2220242025: 002025

南昌有 2 家医院列在烟雾病下全国有 47 家医院列在烟雾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的烟雾病开放试验。

这些数字背后的记录
研究主题影像与脑血流中风与出血
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝豆状核变性

Wilson disease

2021–2025 年中国大陆作者发表的 201 篇肝豆状核变性 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

南昌有 1 家医院列在肝豆状核变性下全国有 28 家医院列在肝豆状核变性下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝豆状核变性开放试验。

这些数字背后的记录
研究主题遗传学(ATP7B)治疗(螯合剂、锌剂)诊断与铜代谢检测
论文中的科室消化/肝病科肾内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年没有牵头大动脉炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南昌有 3 家医院列在大动脉炎下全国有 100 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis即将招募NCT07451665研究中心IV期2026-04 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

南昌有 4 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录
牵头的论文1
  1. Follicular helper T cells and fibrotic diseases.2025Cellular immunology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

南昌有 4 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.9%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

南昌有 1 家医院列在杜氏肌营养不良下全国有 111 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 10 篇,占 1.4%。

牵头论文
10
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 3320232024: 1120242025: 442025

南昌有 4 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科
牵头的论文10
  1. Efficacy and safety of hydroxychloroquine in IgA nephropathy with nasopharyngeal or intestinal mucosal and non-mucosal infections.2025BMC nephrology
  2. IgA vasculitis with nephritis: an overview of the pathogenesis and clinical characteristics.2025Clinical and experimental rheumatology
  3. Glycine decarboxylase advances IgA nephropathy by boosting mesangial cell proliferation through the pyrimidine pathway.2025EMBO molecular medicine
  4. Glomerular mesangial cells derived complement factor H regulates complement activation, influences cell proliferation, and maintains actin cytoskeleton.2025International immunopharmacology
  5. The efficacy of rituximab in the treatment of IgA vasculitis nephritis.2024Clinical and experimental medicine
  6. The role of mononuclear phagocyte system in IgA nephropathy: pathogenesis and prognosis.2023Frontiers in immunology
  7. New insights into the mucosal immune pathogenesis of IgA nephropathy from the perspective of COVID-19 vaccination.2023QJM : monthly journal of the Association of Physicians
  8. New-onset IgA nephropathy following COVID-19 vaccination.2023QJM : monthly journal of the Association of Physicians
  9. Effectiveness and safety of tacrolimus treatment for IgA nephropathy: A prospective cohort study.2022Medicina clinica
  10. Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy.2021BMC nephrology
早期论文(2016–2020 年)2
  1. Differential expression of urinary exosomal microRNAs in IgA nephropathy.2018Journal of clinical laboratory analysis
  2. Efficacy and Safety of Agents in IgA Nephropathy: An Update Network Meta-Analysis.2018Kidney & blood pressure research
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases即将招募NCT06774664研究中心I/II期2025-01 启动
  2. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动
  3. Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy状态不明NCT02231125研究中心IV期2014-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

南昌有 2 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录
论文中的科室风湿免疫科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

南昌有 2 家医院列在原发性硬化性胆管炎下全国有 89 家医院列在原发性硬化性胆管炎下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
    分期
    III期
    开始
    2026-05
    登记号
    NCT07387549

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、天津、广州、济南、郑州、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年没有牵头家族性腺瘤性息肉病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南昌有 1 家医院列在家族性腺瘤性息肉病下全国有 74 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

南昌大学第二附属医院

Second Affiliated Hospital of Nanchang University

南昌

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Nanchang University Second Affiliated Hospital; Second Affiliated Hospital of Nanchang Medical College; second affiliated hospital of Nanchang university; Second Affiliated Hospital of Nanchang University Nanchang; No.2 Affiliated Hospital of Nanchang University

提出更正下载数据